SOAT1 and familial pancreatic carcinoma: This is supported by evidence that the JAK-STAT inhibitor, Ruxolitinib, successfully reduces systemic inflammation within the tumor microenvironment, thereby increasing the infiltration and activation of CTLs and helping to counteract the resistance of pancreatic cancer to anti-PD-1 immunotherapy [145].